Pirtobrutinib, Liso-Cel Could Expand Treatment Arsenal for Relapsed/Refractory CLL
September 5th 2023
Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.